Company Overview: SRPT

Upcoming Projects (SRPT)

Don’t see a project related to the company you care about? Create your own!

Executed Projects (SRPT)

Reviewing the recent Duchenne Muscular Dystrophy Data from Wave Life Sciences on their exon 53 skipper, WVE-N531
Tickers: WVE, SRPT, RNA, NS Pharma
Executed On: Sep 26, 2024 at 11:00 AM EDT
Reviewing Avidity Bioscience's Phase 1/2 data from their Explore 44 Trial of AOC 1044 for Duchenne Muscular Dystrophy treatment
Tickers: RNA, SRPT
Executed On: Aug 15, 2024 at 04:00 PM EDT
Exploring Sarepta Therapeutics' Elevidys Gene Therapy for Duchenne Muscular Dystrophy ahead of June 21 PDUFA
Ticker: SRPT
Executed On: May 23, 2024 at 01:00 PM EDT
Discussing Sarepta Therapeutics’ gene therapy, ELEVIDYS (delandistrogene moxeparvovec-rokl) and the recently announced results from the Phase 3 EMBARK study.
Ticker: SRPT
Executed On: Nov 03, 2023 at 02:00 PM EDT
Discussing the potential of Sarepta Therapeutics’ investigational gene therapy, SRP-9001 (delandistrogene moxeparvovec) for the treatment of DMD with a pediatric cardiologist.
Ticker: SRPT
Executed On: Apr 11, 2023 at 10:00 AM EDT
Discussing the potential of Sarepta Therapeutics’ investigational gene therapy, SRP-9001 (delandistrogene moxeparvovec) for the treatment of DMD with a pediatric neurologist.
Ticker: SRPT
Executed On: Apr 04, 2023 at 08:30 AM EDT
Discussion of SRP-9001, expectations for possible AA and outlook for EMBARK Trial
Ticker: SRPT
Executed On: Oct 11, 2022 at 01:00 PM EDT
Digesting the recent data from Sarepta's SRP-9001-102 study in treating Duchenne Muscular Dystrophy
Ticker: SRPT
Executed On: Jan 18, 2022 at 04:00 PM EST

Expired Projects (SRPT)

Discussing Sarepta’s Gene Therapy Pipeline in Treating Limb-Girdle Muscular Dystrophy
Ticker: SRPT
Execute By: Oct 29, 2021
Discussing the Potential of Summit's (SMMT) Ezutromid in Duchenne Muscular Dystrophy After Initiation of Phase 2 Enrollment
Tickers: SMMT, SRPT
Execute By: Jan 04, 2017
What Does Sarepta’s Exon 51 Approval Mean for its 9 Other Exon Skipping Product Candidates and Company Future?
Ticker: SRPT
Execute By: Nov 11, 2016
After a roller coaster year for DMD treatments and the recent granting of Rare Pediatric Disease designation from the FDA for ezutromid does it have potential in DMD?
Tickers: SMMT, SRPT, BMRN, PTCT
Execute By: Oct 14, 2016
Take 2: Eteplirsen Briefing Documents out 4/21/16. Spring has melted the DC snow, has Sarepta's 4 year data done the same to the FDA?
Ticker: SRPT
Execute By: Apr 22, 2016

Upcoming & Overdue Catalysts (SRPT)

Don’t see a catalyst related to the company you care about? Create your own!

Occurred Catalysts (SRPT)

Sarepta Therapeutics (SRPT) Reports Clinical Results from Phase 2 MOMENTUM Study of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 51
Ticker: SRPT
Occurred on: May 03, 2021
Sarepta's (SRPT) Casimersen in Duchenne muscular dystrophy PDUFA date under priority review February 25, 2021
Ticker: SRPT
Occurred on: Feb 25, 2021
Sarepta's (SRPT) Golodirsen (SRP-4053) in Duchenne muscular dystrophy PDUFA date due August 19, 2019
Ticker: SRPT
Occurred on: Aug 19, 2019
Sarepta (SRPT) Expects to Complete Dose-Titration and Open-label Extension Phase 1 Study of SRP-4045 in Advanced Stage Duchenne Muscular Dystrophy (DMD) Patients in April 2018
Ticker: SRPT
Occurred on: Nov 26, 2018
Preliminary Results Presented from the First Three Children Dosed in Sarepta's (SRPT) Phase 1/2a AAVrh74.MHCK7.micro-Dystrophin Gene Therapy Trial in Duchenne Muscular Dystrophy
Ticker: SRPT
Occurred on: Jun 19, 2018
Phase 1/2 data of Sarepta's (SRPT) MYO-101 in Duchenne muscular dystrophy - LGMD2E due February 27, 2019
Ticker: SRPT
Occurred on: Feb 27, 2018
Preliminary read out of open label Phase 3 study in DMD of eteplirsen
Tickers: SRPT, BMRN, PTCT
Occurred on: Dec 27, 2017
Phase 1/2 Study of Exon-Skipping Candidate SRP-4053 for Exon 53 Continues to Enroll Patient - Data Readout Expected H1 of 2017
Ticker: SRPT
Occurred on: Sep 06, 2017
Data from First Set of 24-week Biopsies Expected Q2 or Q3 for UK Enrolled DMD patients in the Ongoing PhaseOut DMD trial
Tickers: SMMT, BMRN, SRPT, PTCT
Occurred on: Jun 22, 2017
Sarepta (SRPT) Agrees to Sell Rare Pediatric Disease Priority Review Voucher for $125MM to Unnamed Party
Ticker: SRPT
Occurred on: Feb 21, 2017
Sarepta Therapeutics (SRPT) Announces First Patient Dosed in Phase III Clinical Trial of SRP-4045 and SRP-4053 for the Treatment of Duchenne Muscular Dystrophy Amenable to Exon 45 or 53 Skipping
Ticker: SRPT
Occurred on: Sep 28, 2016
Sarepta (SRPT) Wins Patent Fight Against BioMarin (BMRN) for Use of Exon 51 Antisense Oligonucleotides to Treat Duchenne Muscular Dystrophy (DMD)
Tickers: SRPT, BMRN
Occurred on: Sep 20, 2016
Sarepta's (SRPT) Eteplirsen Approved by FDA for Duchenne Muscular Dystrophy After Long Approval Process
Tickers: SRPT, BMRN
Occurred on: Sep 19, 2016
Sarepta began recruiting patients for a Phase 3 trial to treat Duchenne muscular dystrophy with its lead product candidate, Eteplirsen
Ticker: SRPT
Occurred on: Aug 03, 2016
Sarepta Therapeutics Announces FDA Request For Dystrophin Data Prior To Making A Decision on Eteplirsen NDA
Ticker: SRPT
Occurred on: Jun 06, 2016
Sarepta Therapeutics Announces FDA Will Not Complete the Review of the Eteplirsen New Drug Application By The PDUFA Date
Ticker: SRPT
Occurred on: May 25, 2016
Eteplirsen PDUFA goal date extended by standard extension period of three months to May 26, 2016
Ticker: SRPT
Occurred on: May 25, 2016
FDA Advisory committee meeting for Sarepta Therapeutics' Eteplirsen
Tickers: SRPT, PTCT, BMRN
Occurred on: Apr 25, 2016
Sarepta Therapeutics Announces FDA Advisory Committee Meeting to Review Eteplirsen as a Treatment for Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping
Ticker: SRPT
Occurred on: Apr 25, 2016
PDUFA action date for completion of FDA review of the eteplirsen NDA due February 26, 2016
Ticker: SRPT
Occurred on: Mar 14, 2016
FDA Postpones Advisory Committee Meeting to Review Eteplirsen Due to Severe Weather Storm in the Washington D.C. Area; A future meeting date will be announced in the Federal Register
Ticker: SRPT
Occurred on: Jan 20, 2016
FDA decision on Drisapersen approval in DMD: PDUFA 12/27/15
Tickers: BMRN, SRPT, PTCT
Occurred on: Jan 14, 2016
FDA Will Review BioMarin's (BMRN) New Drug Application for Duchenne Muscular Dystrophy Candidate Drisapersen on November 24, 2015
Tickers: BMRN, SRPT, PTCT
Occurred on: Nov 24, 2015
Sarepta (SRPT) Doses First Patient in Phase 1 4045-101 Dose-Titration and Open-label Extension Study of SRP-4045 in Advanced Stage Duchenne Muscular Dystrophy (DMD) Patients
Ticker: SRPT
Occurred on: Oct 01, 2015

Strategic Initiatives (SRPT)

Sarepta (SRPT) Announces $300 MM Offering of Common Stock at $59.75 Per Share to Fund Further Clinical Trials, Commercialization, Manufacturing, Business Development, and Potential Licensing or Acquisition of Complementary Products
Tickers: SRPT, GS, JPM, CS
Announcement Date: Sep 22, 2016
Sarepta Announces Long Term Plan to Consolidate Facilities within Massachusetts
Ticker: SRPT
Announcement Date: Mar 08, 2016

SRPT Overview